GrowthCap’s Post

Should be an engaging and insightful discussion! Looking forward to hearing from this esteemed panel. #allogeneic #celltherapy #celltherapymanufacturing #atmps #advancedtherapies #cellandgenetherapy

🔬 Are you asking questions about DUB inhibitors, DUBTACs, and DUB-targeting PROTACs? The modulation of DUB activity through DUB inhibitors, DUBTACs, and DUB-targeting PROTACs is rapidly opening new opportunities for the development of novel therapeutics in disease areas of high unmet need. Schedule a meeting with our Head of Business Development, Hozefa Amijee, at #BIOEuropeSpring to discuss how you can access our DUB-focused drug discovery platform, capabilities, and asset pipeline to power therapeutic advances in this space. You can arrange a one-to-one meeting through partneringONE (https://rb.gy/l7o212), or contact Hoze directly at [email protected]. #Biotech #DrugDiscovery #DrugDevelopment #Pharma #DUBTAC #StrategicPartnerships

🇺🇸📈The stocks with the highest growth for the week in the Russell 2000 index: ⠀   1. Lumen Technologies, Inc. (#LUMN) - +81.43%; 2. G1 Therapeutics, Inc. (#GTHX) - +78.14%; 3. Iteris, Inc. (#ITI) - +62.04%; 4. Digital Turbine, Inc. (#APPS) - +57.58%; 5. Upstart Holdings, Inc. (#UPST) - +52.57%. 🇺🇸📉The stocks with the biggest decline over the week in the Russell 2000 index: 1. SunPower Corporation (#SPWR) - -76.00%; 2. Elevation Oncology, Inc. (#ELEV) - -67.20%; 3. Actinium Pharmaceuticals (#ATNM) - -66.70%; 4. ThredUp Inc. (#TDUP) - -65.93%; 5. FibroBiologics, Inc. (#FBLG) - -59.55%. #RUT #USA #StockMarket

https://lnkd.in/e3pKeuvW Sheppard Mullin Advises Unicycive Therapeutics in $50 Million Private Placement The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $50 million private placement. The financing is led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing healthcare institutional investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital and Walleye Capital. Sheppard Mullin previously advised Unicycive in its $130 million private placement in March 2023. #biotech #clinicaltrials #financing #corporatelaw #lifesciences #pharmaceutical #patentlaw #patents #investors #privateplacement #therapeutics #bestinclass #clinicaldevelopment #shares #preferredequity #kidneydisease #dialysis #treatment #productlaunch #capitalraising #securitieslaw #nda #fda #drugdevelopment #phosphate #patentprotection #nce #chemical #acute #kidneyhealth #fdacompliance #nanoparticles #pharmaceutical #therapies #innovation #sec

Explore the evolving landscape of Revive Therapeutics: A detailed look at the company's stock performance contrasted with its groundbreaking work in long COVID diagnostics and Bucillamine research. A must-read for professionals interested in biotech innovation and investment insights. #ReviveTherapeutics #HealthcareInnovation #BiotechIndustry https://bit.ly/3sJWDoa

Weight loss therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030) https://lnkd.in/ervsXizE #marketanalysis #marketresearch #marketresearchreports #businessintelligence

𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐧𝐠 𝐨𝐧 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬 𝐰𝐢𝐭𝐡 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐭𝐚𝐥𝐞𝐧𝐭, I've observed a concerning trend in the industry... ▶ Notably, companies like Exelixis, HemoShear Therapeutics, BAKX Therapeutics, SpringWorks Therapeutics, and Redona Therapeutics have recently announced significant cuts to their R&D teams. 🌐 Despite positive strides in early-year investments across the industry, the realm of Pre Clinical R&D continues to face challenges. It's a critical phase in the development process, and the recent workforce reductions raise questions about the sustainability of this trend. 🤔 Can this trajectory persist? The abundance of exceptional Pre Clinical experts currently in the job market is noteworthy. When the market rebounds, and it will, there will be a surplus of personnel ready to contribute their expertise and elevate start-ups in the space. 📈 What trends are you currently observing in the market? Let's discuss present state of the industry and share insights on how we can navigate these challenges together. #biotechnology #drugdiscovery #researchanddevelopment #preclinical

If you're heading to Bio-Europe Spring in a couple of weeks and you have any interest at all in the world of DUBs, go and see Hozefa Amijee - the Ubiquigent Ltd team are genuine world experts in this space.... #biotechnology #biotech #drugdiscovery #drugdevelopment #bioeuropespring

The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. https://lnkd.in/g-EgHmvk #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Syntara is experiencing a surge in valuation, with recent equity research from MST Access highlighting the significant value in their pipeline and driving their share price valuation to A$0.20 per share (up from A$0.02). The exciting potential of their lead drug, SNT-5505, is driving this significant increase. The company's financials are looking healthy after the mannitol business exit, with a current cash balance of $7.2 million that will be boosted by a further $7m related to the mannitol business divestment and an R&D tax credit later in the year. The Phase 2 trial for SNT-5505 as a treatment for #myelofibrosis is exceeding expectations in terms of recruitment and could reach its target enrolment by the end of June. Interim results for this trial are also expected in December 2024. With four Phase 2 trials currently underway, Syntara's deep clinical pipeline has the potential to deliver a steady stream of positive news over the next 18 months. #Syntara #SNT #ASX #ClinicalTrials #Pharmaceuticals #Healthcare #biotech #smallcaps #biotechnology #cancer #bonemarrowcancer #equityresearch #researchreport